ReviewInternational journal of medical sciences2013
EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.
Review in International journal of medical sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03090815 (Circulating Tumor DNA), which is not on this map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma
Who cites it
53 citing papers in PubMed, 117 citations in OpenAlex.
- Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients.British journal of cancer · 2016Trial
- His-tagged pro-apoptotic peptides: enhancing cell internalization and anticancer effect in vitro.Apoptosis : an international journal on programmed cell death · 2025Article
- Review
- Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study.BMC cancer · 2023Article
- CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer.Cell death & disease · 2023Article
- Modified gefitinib conjugated FeFrontiers in bioengineering and biotechnology · 2023Article
- A pharmacological exploration of targeted drug therapy in non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2022Review
- Dissecting the Oncogenic Roles of Keratin 17 in the Hallmarks of Cancer.Cancer research · 2022Article
- Regulation of a Novel Splice Variant of Early Growth Response 4 (EGR4-S) by HER+ Signalling and HSF1 in Breast Cancer.Cancers · 2022Article
- Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.Frontiers in oncology · 2022Review
- Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.International journal of molecular sciences · 2021Review
- KScientific reports · 2021Article
- Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment.MedComm · 2021Review
- Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review.International journal of molecular sciences · 2021Review
- Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma.Scientific reports · 2021Article
- Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021Article
- TGF-β Signaling and Resistance to Cancer Therapy.Frontiers in cell and developmental biology · 2021Review
- Article
- Ligustrazine eases lung cancer by regulating PTEN and Wnt/β-catenin pathway.Translational cancer research · 2020Article
- Combined treatment with N-acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line.Cancer medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a benefit in terms of survival from treatment with an epidermal growth factor receptor targeted therapy is still in debate, while there is a convincing evidence on the predictive role of the EGFR mutational status with regard to the response to tyrosine kinase inhibitors (TKIs).This is a literature overview on the state-of-the-art of EGFR oncogenic mutation in NSCLC. It is designed to highlight the preclinical rationale driving the molecular footprint assessment, the progressive development of a specific pharmacological treatment and the best method to identify those NSCLC who would most likely benefit from treatment with EGFR-targeted therapy. This is supported by the belief that a rationale for the prioritization of specific regimens based on patient-tailored therapy could be closer than commonly expected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.